SECURITIES AND EXCHANGE COMMISSION

                        WASHINGTON, D.C.  20549

                               FORM 8-K

                            CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934



Date  of Report (Date of earliest event reported)   JUNE 30, 1995       ENZON,

INC.

                   (Exact  name  of  registrant  as  specified in its charter)




       DELAWARE                    0-12957              22-237286
   (State or other jurisdiction   (Commission          (IRS Employer
       of incorporation)         File Number)          Identification)



        20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
          (Address of principal executive offices)       (Zip Code)



Registrant's telephone number, including area code    (908) 980-4500




     (Former name or former address, if changed since last report)


ITEM 5.  OTHER EVENTS

     Enzon,  Inc.  ("Enzon" or the "Company") and Schering  Corporation,  a
subsidiary  of  Schering-Plough   Corporation  ("Schering"),  have  further
amended  (the  "Revised  Agreement")  their   November   1990  license  and
development  agreement for PEG-INTRON A (the "Original Agreement").   Under
the Revised Agreement,  Schering  will  obtain Enzon's proprietary know-how
for PEG-Intron A and acquire manufacturing  rights previously held by Enzon
with respect to manufacturing PEG-Intron A.   Enzon has an option to become
Schering's exclusive manufacturer of PEG-INTRON  A  for  the  U.S.  market.
Schering will retain exclusive worldwide marketing rights for PEG-INTRON  A
and continue to be responsible for conducting clinical studies and securing
regulatory  approval.   Enzon is entitled to receive the milestone payments
and royalties provided by  the  Original  Agreement.   In  addition to such
milestone payments, Schering paid to Enzon a $2,000,000 license fee with an
additional  $1,000,000  to  be  paid  upon  completion  of  the  technology
transfer.   Last  quarter  Enzon  delivered  to  Schering two PEG-INTRON  A
formulations  having improved performance characteristics  for  anticipated
clinical trials.

     Concurrently  with executing the Revised Agreement, Schering purchased
847,849 shares (the  "Shares") of Enzon's common stock, $.01 par value, for
aggregate  consideration   of   $2,000,000.    Schering   received   demand
registration  rights exercisable no sooner than January 1996 and piggy-back
registration rights with respect to the Shares.


                            SIGNATURES


     Pursuant to  the  requirements of the Securities Exchange Act of 1934,

the Registrant has duly  caused  this  report to be signed on its behalf by

the undersigned hereunto duly authorized.



Dated:  July 20, 1995




                                              ENZON, INC.
                                             (Registrant)

                                   By:   /S/  JOHN  A.  CARUSO      John A.
Caruso
                                         Vice President,Business Development
                                         and General Counsel